Striatal proteomic analysis suggests that first L-dopa dose equates to chronic exposure

PLoS ONE

Volumn 3, Issue 2, 2008, Pages

  Scholz, Birger ^a   Svensson, Marcus ^a   Alm, Henrik ^a   Sköld, Karl ^a   Fälth, Maria ^a   Kultima, Kim ^a   Guigoni, Céline ^b   Doudnikoff, Evelyne ^b   Li, Qin ^c   Crossman, Alan R ^d   Bezard, Erwan ^b   Andrén, Per E ^a  

^a UPPSALA UNIVERSITY   (Sweden)

^b UNIVERSITÉ DE BORDEAUX   (France)

^c INSTITUTE OF LABORATORY ANIMAL SCIENCE   (China)

^d UNIVERSITY OF MANCHESTER   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

1 ALKYL 2 ACETYLGLYCEROPHOSPHOCHOLINE ESTERASE; ACTIN; ALDEHYDE DEHYDROGENASE; ALPHA TUBULIN; BENSERAZIDE PLUS LEVODOPA; BETA TUBULIN; CCAAT ENHANCER BINDING PROTEIN EPSILON; DYNAMIN I; ELECTRON TRANSFERRING FLAVOPROTEIN; ELONGATION FACTOR 1; ELONGATION FACTOR 1 DELTA; ENOYL COENZYME A HYDRATASE; GLUTAMATE DEHYDROGENASE; GLUTAMATE DEHYDROGENASE 1; HEAT SHOCK PROTEIN 60; HEMOGLOBIN B; HEMOGLOBIN CHAIN; LEVODOPA; MALATE DEHYDROGENASE; NEUROFILAMENT M PROTEIN; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE DEHYDROGENASE; UBIQUINOL CYTOCHROME C REDUCTASE; UBIQUITIN THIOLESTERASE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DOSE RESPONSE; DRUG EFFICACY; DYSKINESIA; FEMALE; GENE EXPRESSION PROFILING; LONG TERM CARE; MASS SPECTROMETER; MONKEY; NERVE CELL PLASTICITY; NONHUMAN; PARKINSON DISEASE; PROTEIN ANALYSIS; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN PHOSPHORYLATION; PROTEIN PROCESSING; PROTEIN SYNTHESIS; SHORT COURSE THERAPY; SINGLE DRUG DOSE; TREATMENT RESPONSE; TWO DIMENSIONAL GEL ELECTROPHORESIS; ANIMAL; CHEMISTRY; CORPUS STRIATUM; DISEASE MODEL; MACACA; MASS SPECTROMETRY; METABOLISM; METHODOLOGY; PROTEOMICS; RAT;

ANIMALS; CORPUS STRIATUM; DISEASE MODELS, ANIMAL; DYSKINESIA, DRUG-INDUCED; ELECTROPHORESIS, GEL, TWO-DIMENSIONAL; LEVODOPA; MACACA; MASS SPECTROMETRY; PARKINSON DISEASE; PROTEIN PROCESSING, POST-TRANSLATIONAL; PROTEOMICS; RATS;

EID: 42449149436     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0001589     Document Type: Article

References (60)

1. Marsden CD, Parkes JD, Quinn N (1982) Fluctuations of disability in Parkinson's disease-clinical aspects. In: Marsden CD, Fahn S, eds. Movement disorders. London: Butterworth. pp 96-122.
2. Bezard E, Brotchie JM, Gross CE (2001) Pathophysiology of levodopa-induced dyskinesia : Potential for new therapies. Nature Rev Neurosci 2: 577-588.
3. Brotchie J (2005) Nondopaminergic mechanisms in levodopa-induced dyskinesia. Movement Disorders 20: 919-931.
4. Berke JD, Paletzki RF, Aronson GJ, Hyman SE, Gerfen CR (1998) A complex program of striatal gene expression induced by dopaminergic stimulation. J Neurosci 18: 5301-5310.
5. 2 dopamine receptor-regulated gene expression of striatonigral and striato-pallidal neurons. Science 250: 1429-1432.
6. Kultima K, Scholz B, Alm H, Skold K, Svensson M, et al. (2006) Normalization and expression changes in predefined sets of proteins using 2D gel electrophoresis: a proteomic study of L-DOPA induced dyskinesia in an animal model of Parkinson's disease using DiGE. BMC Bioinformatics 7:475.
7. Ernst J, Nau, GJ, Bar-Joseph Z (2005) Clustering short time series gene expression data. Bioinformatics 21: i159-168.
8. Aubert I, Guigoni C, Hakansson K, Li Q, Dovero S, et al. (2005) Increased D1 dopamine receptor signaling in levodopa-induced dyskinesia. Annals of Neurology 57: 17-26.
9. Aubert I, Guigoni C, Li Q, Dovero S, Bioulac BH, et al. (2007) Enhanced Preproenkephalin-B-Derived Opioid Transmission in Striatum and Subthalamic Nucleus Converges Upon Globus Pallidus Internalis in L-3,4-dihydroxyphenyl-alanine-Induced Dyskinesia. Biological Psychiatry 61: 836-844.
10. Bezard E, Ferry S, Mach U, Stark H, Leriche L, et al. (2003) Attenuation of levodopa-induced dyskinesia by normalizing dopamine D3 receptor function. Nat Med 9: 762.
11. Nadjar A, Brotchie JM, Guigoni C, Li Q, Zhou S-B, et al. (2006) Phenotype of Striatofugal Medium Spiny Neurons in Parkinsonian and Dyakinetic Nonhuman Primates: A Call for a Reappraisal of the Functional Organization of the Basal Ganglia. J Neurosci 26: 8653-8661.
12. Guigoni C, Dovero S, Aubert I, Qin L, Bioulac BH, et al. (2005) Levodopa-induced dyskinesia in MPTP-treated macaque is not dependent of the extent and pattern of the nigrostrial lesion. Eur J Neurosci 22: 283-287.
13. Alm H, Scholz B, Fischer C, Kultima K, Viberg H, et al. (2006) Proteomic evaluation of neonatal exposure to 2,2 4,4 5-pentabromodiphenyl ether. Environ Health Perspect 114: 254-259.
14. Cohen P (2001) The role of protein phosphorylation in human health and disease. Delivered on June 30th 2001 at the FEBS Meeting in Lisbon. European Journal of Biochemistry 268: 5001-5010.
15. Subramanian A, Tamayo P, Mootha VK, Mukherjee S, Ebert BL, et al. (2005) Gene set enrichment analvsis: a knowledge-based approach for interpreting genome-wide expression profiles. Proc Natl Acad Sci U S A 102: 15545-15550.
16. Andrieux A, Salin PA, Vernet M, Kujala P, Baratier J, et al. (2002) The suppression of brain cold-stable microtubules in mice induces synaptic defects associated with neuroleptic-sensitive behavioral disorders. Genes Dev 16: 2350-2364.
17. van Rossum D, Hanisch U-K (1999) Cytoskeletal dynamics in dendritic spines: direct modulation by glutamate receptors? Trends in Neurosciences 22: 290.
18. Guzowski JF, Timlin JA, Roysam B, McNaughton BL, Worley PF, et al. (2005) Mapping behaviorally relevant neural circuits with immediate-early gene expression. Current Opinion in Neurobiology 15: 599.
19. Tsokas P, Grace EA, Chan P, Ma T, Sealfon SC, et al. (2005) Local Protein Synthesis Mediates a Rapid Increase in Dendritic Elongation Factor 1A after Induction of Late Long-Term Potentiation. J Neurosci 25: 5833-5843.
20. Karpova A, Mikhaylova M, Thomas U, Knopfel T, Behnisch T (2006) Involvement of Protein Synthesis and Degradation in Long-Term Potentiation of Schaffer Collateral CA1 Synapses. J Neurosci 26: 4949-4955.
21. Schuman EM, Dynes JL, Steward O (2006) Synaptic Regulation of Translation of Dendritic mRNAs. J Neurosci 26: 7143-7146.
22. Brown AM, Deutch AY, Colbran RJ (2005) Dopamine depletion alters phosphorylation of striatal proteins in a model of Parkinsonism. European Journal of Neuroscience 22: 247-256.
23. Mann M, Jensen ON (2003) Proteomic analysis of post-translational modifications. Nat Biotech 21: 255.
24. Calabresi P, Picconi B, Tozzi A, Di Filippo M (2007) Dopamine-mediated regulation of corticostriatal synaptic plasticity. Trends Neurosci 30: 211-219.
25. Derkach VA, Oh MC, Guire ES, Soderling TR (2007) Regulatory mechanisms of AMPA receptors in synaptic plasticity. Nat Rev Neurosci 8: 101.
26. Day M, Wang Z, DingJ, An X, Ingham CA, et al. (2006) Selective elimination of glutamatergic synapses on striatopallidal neurons in Parkinson disease models. Nat Neurosci 9: 251.
27. Stephens B, Mueller AJ, Shering AF, Hood SH, Taggart P, et al. (2005) Evidence of a breakdown of corticostriatal connections in Parkinson's disease. Neuroscience 132: 741.
28. Guigoni C, Doudnikoff E, Li Q, Bloch B, Bezard E (2007) Altered D1 dopamine receptor trafficking in parkinsonian and dyskinetic non-human primates. Neurobiol Dis 26: 452-463.
29. Cepeda C, Levine MS (2006) Where Do You Think You Are Going? The NMDA-D1 Receptor Trap. Sci STKE 2006: pe20-.
30. Yudkoff M, Daikhin Y, Nissim I, Horyn O, Luhovyy B, et al. (2005) Brain Amino Acid Requirements and Toxicity: The Example of Leucine. J Nutr 135: 1531S-1538.
31. Nadjar A, Gerfen CR, Bezard E (2007) Priming for L-dopa-induced dyskinesia in Parkinson's disease: Myth or reality? Prog Neurobiol submitted.
32. Bezard E, Dovero S, Prunier C, Ravenscroft P, Chalon S, et al. (2001) Relationship between the Appearance of Symptoms and the Level of Nigrostriatal Degeneration in a Progressive 1-Methyl-4-Phenyl-1,2,3,6-Tetrahydropyridine-Lesioned Macaque Model of Parkinson's Disease. J Neurosci 21: 6853-6861.
33. Hochn HM, Yahr MD (1967) Parkinsonism: onset, progression and mortality. Neurology 17: 427-442.
34. Brooks DJ, Ibanez V, Sawle GV, Quinn N, Lees AJ, et al. (1990) Differing patterns of striatal 18F-dopa uptake in Parkinson's disease, multiple system atrophy, and progressive supranuclear palsy. Ann Neurol 28: 547-555.
35. Kish SJ, Shannak K, Hornykiewicz O (1988) Uneven pattern of dopamine loss in the striatum of patients with idiopathic Parkinson's disease. Pathophysiologic and clinical implications. N Engl J Med 318: 876-880.
36. Schneider JS, Gonczi H, Decamp E (2003) Development of levodopa-induced dyskinesias in parkinsonian monkeys may depend upon rate of symptom onset and/or duration of symptoms. Brain Res 990: 38-44.
37. Kerr JND, Wickens JR (2001) Dopamine D-1/D-5 Receptor Activation Is Required for Long-Term Potentiation in the Rat Neostriatum In Vitro. J Neurophysiol 85: 117-124.
38. Engert F, Bonhoeffer T (1999) Dendritic spine changes associated with hippocampal long-term synaptic plasticity. Nature 399: 66.
39. Centonze D, Picconi B, Gubellini P, Bernardi G, Calabresi P (2001) Dopaminergic control of synaptic plasticity in the dorsal striatum. European Journal of Neuroscience 13: 1071-1077.
40. Picconi B, Centonze D, Hakansson K, Bernardi G, Greengard P, et al. (2003) Loss of bidirectional striatal synaptic plasticity in L-DOPA-induced dyskinesia. Nat Neurosci 6: 501.
41. Picconi B, Pisani A, Baronc I, Bonsi P, Centonze D, et al. (2005) Pathological Synaptic Plasticity in the Suiatuim: Implications for Parkinson's Disease. Neuro Toxicology 26: 779.
42. Gracy KN, Clarke CL, Meyers MB, Pickel VM (1999) N-methyl-D-aspartate receptor 1 in the caudate-putamen nucleus: ultrastructural localization and co-expression with sorcin, a 22,000 mol. wt calcium binding protein. Neuroscicnce 90: 107-117.
43. Waagepetersen HS, Bakken IJ, Larsson OM, Sonnewald U, Schousboe A (1998) Comparison of lactate and glucose metabolism in cultured neocortical neurons and astrocytes using 13C-NMR spectroscopy. Dev Neurosci 20: 310-320.
44. Julien C, Berthiaume L, Hadj-Tahar A, Rajput AH, Bedard PJ, et al. (2006) Postmortem brain fatty acid profile of levodopa-treated Parkinson disease patients and parkinsonian monkeys. Neurochemistry International 48: 404.
45. Samadir P, Grégoire L, Rouillard C, Bédard P, DiPaolo T, et al. (2006) Docosahexaenoic acid reduces levodopa-induced dyskinesias in 1-methyl-4-phenyl-1,2,3,6-,tetrahydropyridine monkeys. Annals of Neurology 59: 282-288.
46. Siniscalchi A, Gallelli L, Mercuri NB, Ibbadu GF, De Sarro, G (2006) Role of lifestyle factors on plasma homocysteine levels in Parkison's disease patients treated with levodopa. Nutr Neurosci 9: 11-16.
47. Frauscher G, Karnaukhova E, Muehl A, Hoeger H, Lubec B (1995) Oral administration of homocysteine leads to increased plasma triglycerides and homocysteic acid - additional mechanisms in homocysteine induced endothelial damage? Life Sciences 57: 813.
48. Zoccolella S, Lamberti P, Iliceto G, Dell'Aquila C, Diroma C, et al. (2006) Elevated plasma homocysteine levels in L-dopa-treated Parkinson's disease patients with dyskinesias. Clin Chem Lab Med 44: 863-866.
49. Bolam JP (1992) Preparation of central nervous system tissue for fight and electron microscopy. In: Experimental neuroanatomy: a practical approach (Rickwood D, Harnes BD, eds): pp. 1-29.
50. Guilloteau D, Emond P, Baulieu JL, Garreau L, Frangin Y, et al. (1998) Exploration ofthe dopamine transporter: in vitro and in vivo characterization of a high-affinity and bigh-specificity iodinated tropane derivative (E)-N-(3-iodoprop-2-enyl)-2b-carbomethoxy-3b-(4′-methylphenyl) nortropane (PE2I). Nucl Med Biol 25: 331-337.
51. Bezard E, Dovero S, Imbert C, Boraud T, Gross CE (2000) Spontaneous long-term compensatory dopaminergic sprouting in MPTP-treated mice. Synapse 38: 363-368.
52. Hallett PJ, Dunah AW, Ravenscroft P, Zhou S, Bezard E, et al. (2005) Alterations of striatal NMDA receptor subunits associated with the development of dyskinesia in the MPTP-lesioned macaque model of Parkinson's disease and dyskinesia. Neuropharmacol 48: 503-516.
53. Levey AI, Hersch SM, Rye DB, Sunahara RK, Niznik HB, et al. (1993) Localization of D1 and D2 dopamine receptors in brain with subtype-specific antibodies. Proc Natl Acad Sci U S A 90: 8861-8865.
54. Hersch SM, Ciliax BJ, Gutekunst CA, Rees HD, Heilman CJ, et al. (1995) Electron microscopic analysis of D1 and D2 dopamine receptor proteins in the dorsal striatum and their synaptic relationships with motor corticostriatal afferents. J Neurosci 15: 5222-5237.
55. Boundly VA, Luedtke RR, Artymyshyn RP, Filtz TM, Molinoff PB (1993) Development of polyclonal anti-D2 dopamine receptor antibodies using sequence-specific peptides. Mol Pharmacol 43: 666-676.
56. Kocher T, Savitski MM, Nielsen ML, Zubarev RA (2006) PhosTShunter: A Fast and Reliable Tool to Detect Phosphorylated Peptides in Liquid Chromatography Fourier Transform Tandem Mass Spectrometry Data Sets. J Proteome Res 5: 659-668.
57. Smyth GK (2004) Linear models and empirical bayes methods for assessing differential expression in microarray experiments. Stat Appl Genet Mol Biol 3: Article3.
58. Smyth GK, Michaud J, Scott HS (2005) Use of within-array replicate spots for assessing differential expression in microarray experiments. Bioinformatics 21: 2067-2075.
59. Lönnstedt I, Speed T (2002) Replicated microarray data. Stat Sinica 12: 31-46.
60. Ernst J, Bar-Joseph Z (2006) STEM: a tool for the analysis of short time series gene expression data. BMC Bioinformatics 7: 191.